JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future

Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs. JAKi are c...

Descripción completa

Detalles Bibliográficos

Autores principales:	Jacopo Angelini, Rossella Talotta, Rossana Roncato, Giulia Fornasier, Giorgia Barbiero, Lisa Dal Cin, Serena Brancati, Francesco Scaglione
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2020-07-01
Colección:	Biomolecules
Materias:	Janus kinases Janus kinase-inhibitors rheumatoid arthritis small molecules
Acceso en línea:	https://www.mdpi.com/2218-273X/10/7/1002
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!